Immediate Versus Late Placement

February 1, 2024 updated by: University Ghent

Alveolar Ridge Preservation With Immediate or Late Implant Placement: a Multicenter Randomized Controlled Trial

Patients in need of a single implant in the premaxilla will be invited to participate in this multicenter randomized controlled trial (RCT). Prior to surgery, a small-field low-dose cone beam computed tomography (CBCT) is taken to verify the integrity of the facial bone wall and an adequate amount of apical and palatal bone dimensions. Sixty patients will be randomly allocated to the test group or control group in 6 centers. Each center receives 10 sealed envelopes (5 are internally labelled with 'delayed implant placement' and 5 with 'immediate implant placement').

For each patient a digital planning is performed in implant planning software and a tooth-supported surgical guide is fabricated prior to tooth extraction.

In the control group, alveolar ridge preservation is performed following tooth extraction. After a healing period of 4 months, a single implant is installed.

In the test group, a single implant is installed immediately after tooth extraction and ridge preservation is performed by filling the gap between the facial bone wall and the implant surface.

A provisional crown is placed at the day of implant surgery, which is replaced by a permanent one 3m later.

Six months after tooth extraction and subsequent ridge preservation, the need for soft tissue grafting is assessed on the base of predetermined criteria (primary outcome measure). Soft tissue augmentation is performed by inserting a palatal connective tissue graft (CTG) into the buccal mucosa at the implant site.

Secondary outcome measures include 3D hard and soft tissue changes as well as clinical, aesthetic, patient-reported and clinician-reported outcomes.

Study Overview

Detailed Description

Patient selection Patients in need of a single implant in the premaxilla (15-25) will be included in this multicenter RCT following screening and after having received written consent.

Sample size calculation A sample size calculation using the Pearson Chi-square test was performed in SAS Power and Sample Size based on a comparison of the proportion on the need for soft tissue augmentation at 5 months following alveolar ridge preservation (ARP) between the control group (ARP + delayed implant placement 'DIP') and test group (ARP + immediate implant placement 'IIP'). The calculation was based on finding a 30% difference between these groups. With alpha set at 0.05 and a power of 0.80, the sample size calculation indicated 28 patients to be included per group. To compensate for drop-outs, 30 patients would be treated with ARP+DIP and 30 would be treated with ARP+IIP.

Clinicians and centers, randomization, allocation concealment and blinding Six experienced clinicians will treat at least 10 patients each. Five clinicians are staff members of the Department of Periodontology and Oral Implantology at UGent - UZ Gent, who also work part-time in different private practices. The final clinician is a professor at the Saint-Luc University Hospital (UCL). The digital workflow, the implant placement protocol, the application of a connective tissue graft (CTG) at 6 months following ARP and the restorative protocol will be thoroughly discussed among the 6 clinicians in a training session before the start of the trial.

During the training session each clinician will receive 5 sealed envelopes internally coded as 'Delayed implant placement' and another 5 as 'immediate implant placement'. Just prior to surgery, a sealed envelope will be randomly selected and opened to reveal the treatment to be conducted. The measuring investigator will not be involved in the treatment of any of the patients and will be blinded to allow unbiased registrations.

Pre-operative digital planning for fabrication of surgical guide A digital workflow will be adopted for every patient for fabrication of a surgical guide prior to tooth extraction. This requires 3D digital implant planning in designated software on the basis of a pre-op low-dose small-field Cone-Beam CT and intra-oral scan. Note that surgical guides for patients in the ARP+DIP group will also be fabricated following patient selection, even though they are only to be used 4 months later.

Control group: ARP+DIP Patients start to take systemic antibiotics (Amoxicilline 1g) and anti-inflammatory medication (Ibuprofen 600 mg) 1h pre-operatively. Following local anesthesia (Septanest special, Septodont, Saint Maur des Fossés, France) and oral disinfection (Corsodyl mouth rinse, GSK, Wavre, Belgium), the failing tooth is extracted without raising a flap. Following socket debridement and rinsing, collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) is applied up to the level of the palatal bone crest and slightly condensed. The occlusal aspect is closed with a collagen matrix (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland), which is fixed with single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to the soft tissues. Post-op instructions include the intake of systemic antibiotics during 4 days (Amoxicilline 1g, two times a day), anti-inflammatory medication as deemed necessary by the patient and oral disinfection twice a day during 1 week. Then, sutures are removed. A removable partial denture as used as provisional tooth replacement when considered needed.

At 4 months, a mucoperiosteal flap is raised, the surgical guide is applied, and the implant is installed according to manufacturer's prescriptions. Then, an implant impression is taken for fabrication of a provisional crown. Prior to wound closure with vertical mattrass sutures (Seralon 6/0, Serag Weissner, Naila, Germany), an appropriate healing abutment is installed. This healing abutment is replaced by the provisional crown two days later.

At 6 months, the need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of screenshots from the pre-op CBCT with lip retractors enabling to evaluate buccal bone and soft tissue thickness. Pre-op clinical pictures, clinical pictures at 6 months with the provisional crown in situ and the STL file at 6 months are also offered to the panel in order to assess the loss of buccal convexity.

Soft tissue augmentation is required necessary when at least one of the following criteria are met: thin gingival biotype as defined as < 1mm midfacial soft tissue thickness as assessed on pre-op CBCT with lip retractors, thin buccal bone wall as defined as < 0.5mm as assessed on pre-op CBCT, loss of ideal buccal convexity at 6 months following ARP as assessed on the basis of clinical pictures and STL. Each clinician makes a decision on the need for soft tissue augmentation for 50 out of 60 cases independent from the other clinicians. Soft tissue augmentation is offered to the patient when the majority of the panel is in favor of it.

Soft tissue augmentation is performed using a CTG harvested from the lateral palate using the single incision technique. At the recipient site, a pouch is made in the buccal mucosa and an appropriately sized CTG is pulled in. The CTG is secured into the buccal mucosa with multiple single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) and the provisional crown is re-installed. Sutures are removed after 1 week. The provisional crown is replaced by a permanent crown 3 months later.

Test group: ARP+IIP Patients start to take systemic antibiotics (Amoxicilline 1g) and anti-inflammatory medication (Ibuprofen 600 mg) 1h pre-operatively. Following local anesthesia (Septanest special, Septodont, Saint Maur des Fossés, France) and oral disinfection (Corsodyl mouth rinse, GSK, Wavre, Belgium), the failing tooth is extracted without raising a flap. Following socket debridement and rinsing, the surgical guide is applied, and the implant is installed according to manufacturer's prescriptions. Then, an implant impression is taken for fabrication of a provisional crown. Finally, the gap is filled with collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland), which is applied up to the level of the free mucosal margin, and an appropriate healing abutment is installed. This healing abutment is replaced by the provisional crown two days later.

At 6 months, the need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of screenshots from the pre-op CBCT with lip retractors enabling to evaluate buccal bone and soft tissue thickness. Pre-op clinical pictures, clinical pictures at 6 months with the provisional crown in situ and the STL file at 6 months are also offered to the panel in order to assess the loss of buccal convexity. Each clinician makes a decision on the need for soft tissue augmentation for 50 out of 60 cases independent from the other clinicians. Soft tissue augmentation is offered to the patient when the majority of the panel is in favor of it.

Soft tissue augmentation is performed using a CTG harvested from the lateral palate using the single incision technique. At the recipient site, a pouch is made in the buccal mucosa and an appropriately sized CTG is pulled in. The CTG is secured into the buccal mucosa with multiple single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) and the provisional crown is re-installed. Sutures are removed after 1 week. The provisional crown is replaced by a permanent crown 3 months later.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Liège, Belgium
        • Recruiting
        • UCL St Luc
        • Contact:
          • Selena Toma
        • Principal Investigator:
          • Selena Toma
    • Oost-Vlaanderen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • at least 18 years old
  • good oral hygiene defined as full-mouth plaque score ≤ 25% (O'Leary et al. 1972)
  • presence of a single-rooted tooth in the anterior maxilla (15-25) that needs to be extracted for any reason with at least one neighboring tooth present
  • at least 3 mm bone available at the apical or palatal aspect of the alveolus to ensure primary implant stability
  • intact or nearly intact buccal bone wall at the time of extraction (max 3 mm bone missing = max 6 mm distance from free gingival margin to buccal bone crest)

Exclusion Criteria:

  • systemic diseases
  • smoking
  • untreated periodontal disease
  • untreated caries lesions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
Delayed implant placement
Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
Experimental: Test group
Immediate implant placement
Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Need for soft tissue augmentation (true or false) as judged by a panel of clinicians
Time Frame: 6 months
The need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of clinical pictures, a CBCT image and STL file.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinician-reported outcome measures
Time Frame: per-op
Ease of implant placement (Visual Analogue Scale). Minimum value = 0 (Very easy) Maximum value = 10 (Very difficult)
per-op
Changes in buccal soft tissue profile
Time Frame: pre-op, 6 months, 1 year, 3 years, 5 years
Volumetric analysis with designated software on the basis of IOS (mm). Change in buccal soft tissue profile and the initial buccal soft tissue profile will be aggregated to calculate relative change in buccal soft tissue profile (=absolute change / initial buccal soft tissue profile, percent)
pre-op, 6 months, 1 year, 3 years, 5 years
Vertical change in midfacial soft tissue level
Time Frame: pre-op, 6 months, 1 year, 3 years, 5 years
Analysed with designated software on the basis of IOS (mm)
pre-op, 6 months, 1 year, 3 years, 5 years
Change in width of the alveolar process
Time Frame: pre-op, 1 year, 5 year
Horizontal measurements with designated software on the basis of CBCT scans (mm)
pre-op, 1 year, 5 year
Change in height of the alveolar process
Time Frame: pre-op, 1 year, 5 year
vertical measurements with designated software on the basis of CBCT scans (mm)
pre-op, 1 year, 5 year
Change in buccal bone thickness
Time Frame: pre-op, 1 year, 5 year
Horizontal measurements with designated software on the basis of CBCT scans (mm)
pre-op, 1 year, 5 year
Implant survival
Time Frame: 6 months, 9 months, 1 year, 3 years, 5 years
presence of the implant
6 months, 9 months, 1 year, 3 years, 5 years
Complication
Time Frame: Up to 5 years
Any complication
Up to 5 years
Changes in radiographic outcomes
Time Frame: implant placement, 1 year, 3 years, 5 years
marginal peri-implant bone level change as assessed by intra-oral radiography (mm)
implant placement, 1 year, 3 years, 5 years
Aesthetic outcome as assessed by care providers
Time Frame: pre-op, 1 year, 3 years, 5 years
Pink Aesthetic Score (0-14) = assessment of 7 different parameters (Mesial papilla, distal papilla, tissue contour, gingival level, alveolar process, coloring, texture) which are all rated 0 (worst) - 2 (best)
pre-op, 1 year, 3 years, 5 years
Aesthetic outcome as assessed by patients
Time Frame: pre-op, 1 year, 3 years, 5 years
Patients aesthetic satisfaction (Visual Analogue Scale) Minimum value = 0 (Very unsatisfied) Maximum value = 10 (Very satisfied)
pre-op, 1 year, 3 years, 5 years
Keratinized mucosa width
Time Frame: pre-op, 1 year, 3 years, 5 years
Vertical measurement performed with a periodontal probe (mm)
pre-op, 1 year, 3 years, 5 years
Probing pocket depth
Time Frame: pre-op, 1 year, 3 years, 5 years
Probing depth measured with a periodontal probe (mm)
pre-op, 1 year, 3 years, 5 years
Bleeding on probing
Time Frame: pre-op, 1 year, 3 years, 5 years
Bleeding on probing was registered 15 seconds following pocket probing at four sites per implant (mesial, distal, buccal, palatal) using a dichotomous score (0: no bleeding; 1: bleeding). These values were averaged and expressed as a percentage on implant level
pre-op, 1 year, 3 years, 5 years
Plaque
Time Frame: pre-op, 1 year, 3 years, 5 years
Plaque was recorded at four sites per implant (mesial, distal, buccal, palatal) using a dichotomous score (0: no visible plaque at the soft tissue margin; 1: visible plaque at the soft tissue margin). These values were averaged and expressed as a percentage on implant level.
pre-op, 1 year, 3 years, 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

October 17, 2020

First Submitted That Met QC Criteria

February 2, 2021

First Posted (Actual)

February 5, 2021

Study Record Updates

Last Update Posted (Estimated)

February 2, 2024

Last Update Submitted That Met QC Criteria

February 1, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esthetics

Clinical Trials on Implant placement (BLX implant system, Straumann, Basel, Switzerland)

Subscribe